Hepatocellular Carcinoma (HCC)
257
95
112
48
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
12 trials with published results (5%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
3.1%
8 terminated out of 257 trials
85.7%
-0.8% vs benchmark
7%
19 trials in Phase 3/4
25%
12 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 48 completed trials
Clinical Trials (257)
A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning.
TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Criteria
A Phase 1 Study of the Safety and Tolerability of CTX-10726
AI-Guided Surveillance and Curative Salvage of Recurrence After Hepatocellular Carcinoma Resection or Ablation
Peripheral Blood Biomarkers and Response to Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Breath Research Narrow Validation for Gastrointestinal Cancer Detection
A Phase 1b Study of GKL-006 Injection in Patients With Unresectable Hepatocellular Carcinoma
Application of Super-Resolution Ultrasound (SRUS) in Liver Tumor
Safety and Feasibility of CIK Cell Therapy in HCC After Tumor Resection
FAPI PET Imaging - An Exploratory Study
Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma
HCC-MPDS Multimodal Deep Learning Prognostic Model for Resectable HCC
Estimation and Prediction of Individual Benefit From Postoperative Adjuvant Transcatheter Arterial Chemoembolization For Patients With Hepatocellular Carcinoma
Adaptive Dosing of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma
Non-Invasive Risk Stratification for Hepatocellular Carcinoma in HCV-Related Compensated Advanced Chronic Liver Disease Following Sustained Virological Response: Validation of the aMAP Score
HCC Risk and Monitoring in Patients With Type 2 Diabetes
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer